Stock Analysis

Is There Now An Opportunity In Porvair plc (LON:PRV)?

  •  Updated
LSE:PRV
Source: Shutterstock

While Porvair plc (LON:PRV) might not be the most widely known stock at the moment, it saw a double-digit share price rise of over 10% in the past couple of months on the LSE. Less-covered, small caps sees more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing. So, could the stock still be trading at a low price relative to its actual value? Let’s take a look at Porvair’s outlook and value based on the most recent financial data to see if the opportunity still exists.

Check out our latest analysis for Porvair

Is Porvair still cheap?

According to my price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average, the stock price seems to be justfied. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 21.66x is currently trading slightly below its industry peers’ ratio of 26.66x, which means if you buy Porvair today, you’d be paying a decent price for it. And if you believe Porvair should be trading in this range, then there isn’t much room for the share price to grow beyond the levels of other industry peers over the long-term. Furthermore, it seems like Porvair’s share price is quite stable, which means there may be less chances to buy low in the future now that it’s priced similarly to industry peers. This is because the stock is less volatile than the wider market given its low beta.

What kind of growth will Porvair generate?

earnings-and-revenue-growth
LSE:PRV Earnings and Revenue Growth December 11th 2020

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. However, with a negative profit growth of -5.2% expected over the next couple of years, near-term growth certainly doesn’t appear to be a driver for a buy decision for Porvair. This certainty tips the risk-return scale towards higher risk.

What this means for you:

Are you a shareholder? Currently, PRV appears to be trading around industry price multiples, but given the uncertainty from negative returns in the future, this could be the right time to de-risk your portfolio. Is your current exposure to the stock beneficial for your total portfolio? And is the opportunity cost of holding a negative-outlook stock too high? Before you make a decision on PRV, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping an eye on PRV for a while, now may not be the most advantageous time to buy, given it is trading around industry price multiples. This means there’s less benefit from mispricing. In addition to this, the negative growth outlook increases the risk of holding the stock. However, there are also other important factors we haven’t considered today, which can help gel your views on PRV should the price fluctuate below the industry PE ratio.

Since timing is quite important when it comes to individual stock picking, it's worth taking a look at what those latest analysts forecasts are. So feel free to check out our free graph representing analyst forecasts.

If you are no longer interested in Porvair, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

If you decide to trade Porvair, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted


Valuation is complex, but we're helping make it simple.

Find out whether Porvair is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis